ZBD(SH:603567) Zheng Quan Zhi Xing·2025-07-24 16:21Core Viewpoint - The company, Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., is implementing a buyback and cancellation of 144,094 restricted stocks due to the departure of three employees, which represents 5.95% of the total stock under the incentive plan and 0.02% of the company's total share capital [1][2]. Group 1: Buyback and Cancellation Details - The buyback and cancellation are based on the provisions of the "Incentive Plan" and the "Management Measures for Equity Incentives of Listed Companies," which stipulate that restricted stocks cannot be released from restrictions if the employee has left the company [2][3]. - The total amount for the buyback is 1,186,181.80 yuan, sourced from the company's own funds [2][3]. - The cancellation of the stocks is expected to be completed by July 29, 2025, with the company having opened a dedicated securities account for this purpose [3]. Group 2: Impact on Share Capital Structure - Following the cancellation, the company's total share capital will decrease from 941,140,609 shares to 940,996,515 shares [3][4]. - The cancellation will not affect the controlling shareholder or the actual controller, and the company's equity distribution will still meet the listing requirements [4]. Group 3: Legal Compliance and Commitments - The board of directors confirmed that the decision-making process and information disclosure comply with relevant laws and regulations, ensuring no harm to the rights of the incentive objects or creditors [4][5]. - The company has committed to handling any disputes arising from this buyback and cancellation responsibly [4][5].